Ventegra adds Celltrion's Humira copy as preferred formulary product

The US subsidiary of South Korea's Celltrion Healthcare (Kosdaq: 068270) has announced the signing of an important contract with Ventegra, a US medical benefits manager (MBM).

Ventegra, which administers pharmacy benefits through a model that has been effectively displacing traditional pharmacy benefit managers (PBMs), will incorporate Yuflyma (adalimumab-aaty) as a preferred drug in its formulary.

"Celltrion is well positioned in the US adalimumab market"Celltrion has billed the deal as an expansion of its presence in the USA, the world's largest and most fiercely-contested market for biosimilars of adalimumab, the inflammatory diseases drug that was originally marketed by AbbVie (NYSE: ABBV) as Humira.